查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387496

皮膚 B 細胞淋巴瘤 (CBCL) 治療市場報告：2030 年趨勢、預測與競爭分析

Cutaneous Bcell Lymphoma Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

皮膚 B 細胞淋巴瘤 (CBCL) 治療趨勢與預測

預計 2024 年至 2030 年，全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場將以 2.3% 的年複合成長率成長。該市場的主要驅動力是擴大採用先進的標靶治療、增加臨床證據的經驗使用以及增加用於治療皮膚 B 細胞淋巴瘤 (CBCL) 的新產品開發的研發投資。全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場前景看好，醫院和專科診所市場蘊含商機。

皮膚 B 細胞淋巴瘤 (CBCL) 治療市場洞察

Lucintel 預測，由於化療對晚期病例的有效性以及對不同疾病階段的適應性，化療將在預測期內達到最高成長。

預計北美地區在預測期內將出現最高的成長。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球皮膚B細胞淋巴瘤（CBCL）治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球皮膚B細胞淋巴瘤（CBCL）治療市場趨勢（2018-2023）與預測（2024-2030）
  • 按類型分類的全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場
    • 放射線治療
    • 化療
    • 單株抗體
    • 其他
  • 全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場（按最終用途）
    • 醫院
    • 專科診所
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場（按地區）
  • 北美皮膚B細胞淋巴瘤（CBCL）治療市場
  • 歐洲皮膚B細胞淋巴瘤（CBCL）治療市場
  • 亞太皮膚 B 細胞淋巴瘤 (CBCL) 治療市場
  • 其他地區皮膚B細胞淋巴瘤（CBCL）治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場成長機會
    • 全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場成長機會（按最終用途）
    • 全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場成長機會（按地區）
  • 全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場的產能
    • 全球皮膚 B 細胞淋巴瘤 (CBCL) 治療市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Kite Pharma
  • Genentech
  • Novartis
  • Epizyme
  • NanoString Technologies
  • Amgen
  • Johnson & Johnson Services
簡介目錄

Cutaneous Bcell Lymphoma Treatment Trends and Forecast

The future of the global cutaneous Bcell lymphoma treatment market looks promising with opportunities in the hospitals, and speciality clinics markets. The global cutaneous Bcell lymphoma treatment market is expected to grow with a CAGR of 2.3% from 2024 to 2030. The major drivers for this market are growing adoption of advanced and targeted therapies, increasing usage of clinical evidence demonstrating, as well as, rising investments in research and development to develop novel products to cure cutaneous Bcell lymphoma.

A more than 150-page report is developed to help in your business decisions.

Cutaneous Bcell Lymphoma Treatment by Segment

The study includes a forecast for the global cutaneous Bcell lymphoma treatment by type, end use, and region.

Cutaneous Bcell Lymphoma Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Radiation Therapy
  • Chemotherapy
  • Monoclonal Antibodies
  • Others

Cutaneous Bcell Lymphoma Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Speciality Clinics
  • Others

Cutaneous Bcell Lymphoma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cutaneous Bcell Lymphoma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cutaneous Bcell lymphoma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cutaneous Bcell lymphoma treatment companies profiled in this report include-

  • Kite Pharma
  • Genentech
  • Novartis
  • Epizyme
  • Nanostring Technologies
  • Amgen
  • Johnson & Johnson Services

Cutaneous Bcell Lymphoma Treatment Market Insights

Lucintel forecasts that chemotherapy is expected to witness highest growth over the forecast period because of its effectiveness in advanced case and adaptability to different disease stages.

North America is expected to witness highest growth over the forecast period.

Features of the Global Cutaneous Bcell Lymphoma Treatment Market

Market Size Estimates: Cutaneous Bcell lymphoma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cutaneous Bcell lymphoma treatment market size by type, end use, and region in terms of value ($B).

Regional Analysis: Cutaneous Bcell lymphoma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, end use, and regions for the cutaneous Bcell lymphoma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cutaneous Bcell lymphoma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for cutaneous Bcell lymphoma treatment market?

Answer: The global cutaneous Bcell lymphoma treatment market is expected to grow with a CAGR of 2.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the cutaneous Bcell lymphoma treatment market?

Answer: The major drivers for this market are growing adoption of advanced and targeted therapies, increasing usage of clinical evidence demonstrating, as well as, rising investments in research and development to develop novel products to cure cutaneous Bcell lymphoma.

Q3. What are the major segments for cutaneous Bcell lymphoma treatment market?

Answer: The future of the global cutaneous Bcell lymphoma treatment market looks promising with opportunities in the hospitals, and speciality clinics markets.

Q4. Who are the key cutaneous Bcell lymphoma treatment market companies?

Answer: Some of the key cutaneous Bcell lymphoma treatment companies are as follows:

  • Kite Pharma
  • Genentech
  • Novartis
  • Epizyme
  • Nanostring Technologies
  • Amgen
  • Johnson & Johnson Services

Q5. Which cutaneous Bcell lymphoma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that chemotherapy is expected to witness highest growth over the forecast period because of its effectiveness in advanced case and adaptability to different disease stages.

Q6. In cutaneous Bcell lymphoma treatment market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cutaneous Bcell lymphoma treatment market by type (radiation therapy, chemotherapy, monoclonal antibodies, and others), end use (hospitals, speciality clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cutaneous Bcell Lymphoma Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cutaneous Bcell Lymphoma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cutaneous Bcell Lymphoma Treatment Market by Type
    • 3.3.1: Radiation Therapy
    • 3.3.2: Chemotherapy
    • 3.3.3: Monoclonal Antibodies
    • 3.3.4: Others
  • 3.4: Global Cutaneous Bcell Lymphoma Treatment Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Speciality Clinics
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cutaneous Bcell Lymphoma Treatment Market by Region
  • 4.2: North American Cutaneous Bcell Lymphoma Treatment Market
    • 4.2.2: North American Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
  • 4.3: European Cutaneous Bcell Lymphoma Treatment Market
    • 4.3.1: European Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
    • 4.3.2: European Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
  • 4.4: APAC Cutaneous Bcell Lymphoma Treatment Market
    • 4.4.1: APAC Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
    • 4.4.2: APAC Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
  • 4.5: ROW Cutaneous Bcell Lymphoma Treatment Market
    • 4.5.1: ROW Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
    • 4.5.2: ROW Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by End Use
    • 6.1.3: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by Region
  • 6.2: Emerging Trends in the Global Cutaneous Bcell Lymphoma Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cutaneous Bcell Lymphoma Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cutaneous Bcell Lymphoma Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Kite Pharma
  • 7.2: Genentech
  • 7.3: Novartis
  • 7.4: Epizyme
  • 7.5: NanoString Technologies
  • 7.6: Amgen
  • 7.7: Johnson & Johnson Services